(12) Patent Application Publication (10) Pub. No.: US 2012/0009150 A1 WEBER Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US 2012O009 150A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0009150 A1 WEBER et al. (43) Pub. Date: Jan. 12, 2012 (54) DIARYLUREAS FORTREATINGVIRUS Publication Classification INFECTIONS (51) Int. Cl. (76) Inventors: Olaf WEBER, Wulfrath (DE); st 2. CR Bernd Riedl, Wuppertal (DE) ( .01) A63/675 (2006.01) (21) Appl. No.: 13/236,865 A6II 3/522 (2006.01) A6IP 29/00 (2006.01) (22) Filed: Sep. 20, 2011 A6II 3/662 (2006.01) A638/14 (2006.01) Related U.S. Application Data A63L/7056 (2006.01) A6IP3L/2 (2006.01) (63) Continuation of application No. 12/097.350. filed on A6II 3/44 (2006.01) Nov. 3, 2008, filed as application No. PCTAEPO6/ A6II 3/52 (2006.01) 11693 on Dec. 6, 2006. O O (52) U.S. Cl. .......... 424/85.6; 514/350; 514/171; 514/81; (30) Foreign Application Priority Data 514/263.38: 514/263.4: 514/120: 514/4.3: Dec. 15, 2005 (EP) .................................. 05O274513 424/85.7; 514/43 Dec. 15, 2005 (EP). ... O5O27452.1 Dec. 15, 2005 (EP). ... O5O27456.2 Dec. 15, 2005 (EP). ... O5O27458.8 The present invention relates to pharmaceutical compositions Dec. 15, 2005 (EP) O5O27.460.4 for treating virus infections and/or diseases caused by virus Dec. 15, 2005 (EP) O5O27462.O infections comprising at least a diary1 urea compound option Dec. 15, 2005 (EP). ... O5O27465.3 ally combined with at least one additional therapeutic agent. Dec. 15, 2005 (EP). ... O5O274.67.9 Useful combinations include e.g. BAY 43-9006 as a diaryl Dec. 15, 2005 (EP) .................................. 05O27471.1 urea compound. US 2012/0009 150 A1 Jan. 12, 2012 DARYLUREAS FORTREATINGVIRUS oviruses such as human Varizella Zoster virus), Betaherpes INFECTIONS viridae (e.g. cytomegalovirus and roseolovirus) and Gamma herpesviridae (e.g. Epstein-Barr virus). Such virus infections can cause e.g. infections of the lymphatic system of the outer 0001. The present invention relates to pharmaceutical genitalia, the lips, the briars (herpesencephalitis) or the compositions for treating virus infections and/or diseases peripheral nerves. caused thereby comprising at least a diaryl urea compound 0009. A number of herpeviruses use the cellular signal optionally combined with at least one additional therapeutic pathways of MAPK/ERK and p38 MAPK, e.g. infection with agent. Useful combinations include e.g. BAY 43-9006 as a herpes simplex virus induce the activation of the p38 MAPK diaryl urea compound. and SAPK/JNK signal pathway (G. Zachos et al., J. Biol. 0002 BAY 43-9006 refers to 4-4-3-(4-chloro-3-trifluo Chem. 1999, 274, 5097). Inhibitors of the MAPK/ERK or the romethylphenyl)-ureidol-phenoxy-pyridine-2-carboxylic p38 MAPK pathway inhibit the activation of early promoters acid methyl amide and is species of diaryl urea compounds of the human cytomegalovirus (J. Chen et al. J. Virol., 2002, which are potent anti-cancer and anti-angiogenic agents that 76 (10), 4873). possess various activities, including inhibitory activity on the 0010. The viruses of the Papovaviridae family comprise VEGFR, PDGFR, rat p38, and/or fit-3 kinase signaling mol the genus papillomaviruses and include a “high risk group of ecules. See, e.g., WO 2004/113274 and WO 2005/000284. viruses (e.g. species HPV 16, 18) and a “low risk” group (e.g. 0003 SARS (severe acute respiratory syndrome) is a dis HPV 6, 11). Human papillomaviruses induce neoplasm of the ease caused by an infection with SARS coronavirus (SARS dermis and can cause the formation of papillomas. Virus CoV) which gets public importance in the last years. For infections of the “low risk” group, however, are associated infected patients the therapeutic standard of today is, how with malignant tumour diseases (e.g. Zervix cancer). Types of ever, low. the “low risk group cause e.g. anogenital warts. An activa 0004. A typical coronavirus is represented by e.g. the tion of the MAPK signal pathway is detected in human pap mouse hepatitis virus (MHV) which induces the p38 kinase illomas infected with papillomaviruses (D. Johnston et al., which is part of the MAPK pathway in infected cells (S. Cancer Res., 1999, 59 (4), 968). Banerjee et al. J. Viral. 2002, 76,5937-5948). Furthermore 0011 Pox were one of the most dreaded diseases in history recent results show that also SARS-CoV induces the signal and deemed to be exterminated in 1977 after introduction of pathway of p38 MAPK in permissive cells (Mizutani et al. immunisation. Today poxviruses Such as the molluscum con Biochem. Biophys. Res. Commun. 2004, 319, 1228-1234). tagiosum virus and poxviruses pathogenic for animals play a 0005. A known standard therapy of HIV (human immu role. The viruses of the Poxyiridae family include the sub nodeficiency virus) infections is HAART (highly active anti family Chordopoxyiridae and comprise avipoxvirus, capri retroviral therapy) wherein a combination of several antiret poxvirus, lepripoxvirus, Suipoxvirus, parapoxvirus, mollus roviral drugs (protease inhibitors and antiretroviral drugs) are cipoxvirus and orthopoxvirus. Such virus infections can administered to infected patients (e.g. a combination of indi cause e.g. Smallpox. Cellular targets are known for the navir, zidovudine and lamivudin). The drugs inhibit the abil therapy of poxvirus infections (H. Yang et al., J. Clin. Invest, ity of the virus to multiply in the body and slow the develop 2005, 115 (2),379). ment of AIDS (acquired immunodeficiency syndrome). 0012. The genus flavivirus and pestivirus especially the 0006 Furthermore it is known that the p38 kinase inhibi yellow fever virus, denguevirus 1 to 4, west nile fever virus, tor RWJ 67657 suppresses the replication of HIV and the spring-Summer encephalitis virus, Omsk-hemorrhagic fever cellular pathogenesis of the infection (K. Muthumani et al. virus, bovine virus-diarrhea-Virus and swine fever virus, AIDS, 2004, 18, 739-748). belong to the Flaviviridae family. Such virus infections can 0007 Hepatitis viruses such as HBV and HCV modulate cause e.g. encephalitis and encephalomyelitis. the MAPK signal pathway in infected cells (M. Panteva et al. Virus Research 2003, 92, 131). A permanent activation of the 0013 Activation of the p38 MAPK signal pathway plays RAF/MEK/ERK signal pathway is detected in cells express an important role for the interaction of Flaviviridae viruses ing HCV Core Protein (S. Giambartolomei et al. Oncogene, and the host cells (C. Chen et al., J. Gen. Viral. 2002, 83, 2001, 20, 2607) and an increased level of N-Ras is important 1897). for the maintenance of the replication of HCV (P. Mannova, 0014. The genus enterovirus, cardiovirus, rhinovirus, aph L. Beretta, J. Virol. 2005, 79 (14), 8742) wherein Ras is tovirus and hepatovirus especially the polio-viruses, coxsack affected by Raf. It is also known that the integrity of the ieviruses, coxsackieviruses, human echoviruses, human RAF/MEK signal cascade is a precondition for the replication enteroviruses, human rhinoviruses and hanks viruses, belong of HBV (L. Stockl, Oncogene, 2003, 22 (17), 260). Influenza to the Picornaviridae family. Such virus infections can cause viruses such as type A, B or C belong to group of OrthomyX e.g. in humans aseptic meningitis, poliomyelitis, herpangina, oviruses and cause every year flu epidemics effecting up to pleurodynia (Bornholm disease), myositis, rhabdomyolysis, 10,000 cases of death per year in Germany. Relevant cellular diabetes type I, summer fever and myocarditis. Furthermore targets for a therapy are known (S. Ludwig et al., Trends Mol. in animals rhinoviruses, and the foot and mouth disease Med., 2003, 46). The p38 MAPK signal pathway is induced in viruses can be caused by Such infections. mouse cells infected with influenza A virus (I. Mori et al., J. (0015. It is shown that inhibition of p38 MAPK can inhibit Gen. Virol. 2003, 84, 2401). Furthermore inhibition of MEK the replication of Picornaviridae viruses (K. Hirasawa et al., J. inhibit the proliferation of influenza V virus in cell cultures Virol. 2003, 77 (10), 5649-5656). (S. Ludwig et al. FEBS Letters, 2004, 561,37). 0016. The present invention provides pharmaceutical 0008. The viruses of the Herpesviridae family comprise compositions for treating virus infections and/or diseases viruses of the Sub-families Alphaherpesviridae (e.g. simplcX caused thereby comprising at least one compound of formula viruses such as human herpes simplex viruses and Varicell I and optionally at least one further therapeutic agent. US 2012/0009 150 A1 Jan. 12, 2012 0017. The present invention provides a therapeutic diseases caused by Such infections comprising at least one method which treat virus infections according to the present compound of formula I and optionally at least one further invention and/or diseases caused by Such infections of therapeutic agent. infected patients more effectively compared to current thera 0027. The present invention provides a therapeutic pies and therefore is Superior to current therapies. The present method which treat Elerpesviridae viruses infections and/or invention can be used e.g. by administering a diary1 urea diseases caused by Such infections of infected patients more compound of formula I and optionally a further therapeutic effectively compared to current therapies and therefore is agent, pharmaceutically-acceptable salts thereof, and deriva Superior to current therapies. The present invention can be tives thereof, etc. used e.g. by administering a diary1 urea compound of formula 0018. The present invention provides pharmaceutical I and optionally a further therapeutic agent, pharmaceuti compositions